MD Magazine

RBX2660 from Rebiotix will be assessed in a randomized study involving 300 patients.

New data for the 2019-2020 season shows the virus is at a high activity, but disease severity is moderate.

In the pivotal assessment, three-quarters of patients who received cefiderocol had resolution of symptoms and eradication of the bacteria 1 week after completing treatment, versus 54.6% of patients who received an alternative antibiotic.

The supplemental new drug application was approved based on results of a phase 3 trial in which IV-to-oral delafloxacin met the primary end point of statistical non-inferiority to moxifloxacin.

Xofluza is currently being evaluated in a phase 3 development program for the reduced transmission of flu from an infected person to healthy people.

A panel discussion on a growing public concern over our ability to treat and prevent dementia.

Considerations for improving upon the diagnosis and management of Alzheimer disease.

An overview of exciting, upcoming therapies that may be of interest for the treatment of Alzheimer disease.

Experts discuss the status of clinical trials that explore various monoclonal antibody therapies and BACE inhibitors for the treatment of Alzheimer disease.

The rationale for investigating monoclonal antibodies and BACE inhibitors for the treatment of patients with Alzheimer disease.

The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.

Drs. Alireza Atri and Ronald C. Petersen remark on the important roles a community neurologist, as well as other members of a patient’s health care team, can play in the management of Alzheimer disease.

The role of clinical trials and the importance of counseling patients on trial enrollment and lifestyle interventions in the management of Alzheimer disease.

Expert clinicians highlight current unmet needs surrounding the treatment of Alzheimer disease.

Moving forward following failed studies in Alzheimer disease and improving how the condition is managed in the future.

An in-depth review of mechanisms linked to the pathogenesis of Alzheimer disease, including amyloid and tau.

Ronald C. Petersen, MD, PhD, discusses the relationship between genetics and the risk for developing Alzheimer disease, as well as highlights efforts of the Generation Program.

How the thought of AD has changed to interpret the disease's pathology, and why that has benefitted clinicians.

With all the talk about a looming physician shortage in the US, it's instructive to see where the US falls in terms of physicians per capita.